Featured Press Releases

Secretome Therapeutics

Secretome Therapeutics' STM-01, a neonatal cardiac progenitor cell therapy for HFpEF, receives FDA Fast Track designation

Formosa Pharmaceuticals Strikes Licensing Deal with Tabuk Pharmaceuticals for Clobetasol Propionate Ophthalmic Suspension

Formosa Pharmaceuticals Strikes Licensing Deal with Tabuk Pharmaceuticals for Clobetasol Propionate Ophthalmic Suspension

  • 09 May 2024

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into an...

Centinel Spine

Centinel Spine's Match-the-Disc™ prodisc® Cervical Total Disc Replacement System has completed over 10,000 procedures in the U.S

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

MinuteClinic highlights improved access and outcomes through its clinically supervised weight-loss program

MinuteClinic highlights improved access and outcomes through its clinically supervised weight-loss program

Industry Veteran Marie Emms Appointed President of Clinical Business at Spectrum Science

Industry Veteran Marie Emms Appointed President of Clinical Business at Spectrum Science

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

  • Merck & Co., Inc.
  • 22 Sep 2026
Stasis Introduces the First Day-and-Night Supplement System Built for Children Who Take Stimulants

Stasis Introduces the First Day-and-Night Supplement System Built for Children Who Take Stimulants

  • Stasis
  • 16 Sep 2026
Chemify Becomes the First Chemistry Hyperscaler with £22 Million in Grants from Scottish Enterprise and the UK Government

Chemify Becomes the First Chemistry Hyperscaler with £22 Million in Grants from Scottish Enterprise and the UK Government

  • Chemify
  • 16 Sep 2026
Lundbeck Receives Marketing Authorization for Vyepti® (eptinezumab) in Japan for the Prevention of Migraine Attacks

Lundbeck Receives Marketing Authorization for Vyepti® (eptinezumab) in Japan for the Prevention of Migraine Attacks

  • H. Lundbeck
  • 16 Sep 2026
Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish a Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish a Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

  • AptarGroup, Inc.
  • 16 Sep 2026
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing

Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing

  • Asahi Kasei
  • 15 Sep 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.